GlassScriptPhysician profile
Kevin K Sohn
NPI 1972723625
$20,660.98
in general payments reported to CMS, 2019-2025
38 companies · $4,427 in 2025
The $4,427 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,816 · 2020: $1,636 · 2021: $2,830 · 2022: $2,795 · 2023: $2,698 · 2024: $3,459 · 2025: $4,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Gift: $81.81 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,490.91 |
| Gift | $81.81 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,586.15 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Amgen INC. | $3,061.79 | 2019-2025 | Evenity, Repatha, Repatha |
| Novo Nordisk INC | $2,006.55 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $1,966.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $1,952.15 | 2021-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Astrazeneca Pharmaceuticals LP | $1,360.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $1,257.31 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $711.79 | 2021-2025 | |
| Corcept Therapeutics | $697.43 | 2024-2025 | Korlym |
| Pfizer INC. | $492.46 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $454.17 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $411.11 | 2019-2025 | Arexvy, Shingrix |
| Braintree Laboratories, INC. | $270.22 | 2020-2023 | Sutab, Suflave |
| Janssen Pharmaceuticals, INC | $238.77 | 2019 | |
| Antares Pharma, INC. | $236.62 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Sohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.